Amos AF, McCarty DJ & Zimmet P 1997 The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14, S1–S85.
Astin JA 1998 Why patients use alternative medicine. Results of a national study. JAMA 279, 1548–1553.
Bailey CJ & Day C 1989 Traditional treatments for diabetes. Diabetes Care 12, 553–564.
Brevoort P 1998 The booming US botanical market – new overview. Herbalgram 44, 33–46.
Clark CJ 1998 The burden of chronic hyperglycaemia. Diabetes Care, C32–C34.
Day CHypoglycaemic compounds from plants. In New Anti-Diabetic Drugs, pp. 267–278 [CJ Bailey and PR Flatt, editors] London: Smith-Gordon. 1990
De Fronzo RA, Banadonna RC & Ferrannini E 1992 Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15, 318–368.
Dunn CJ & Peters DH 1995 Metformin: a review of its pharmacological properties and therapeutic use in NIDDM. Drugs 49, 721–749.
Flatt PR & Bailey CJ 1981 Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573–577.
Foyt HL, Ghazzi MN, Hanley RM, Saltiel AR & Whitcomb RWThiazolidinediones. In Diabetes Mellitus. A Fundamental and Clinical Text, pp. 788–797 [D Le Roith, SI Taylor and JM Olefsky, editors]. Philadelphia: Lippincott, Williams and Wilkins. 2000
Frost SC & Lane MD 1985 Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J Biol Chem 260, 2646–2652.
Gray AM & Flatt PR 1997 Nature's own pharmacy: the diabetes perspective. Proc Nutr Soc 56, 507–517.
Hunt SM, Chrzanowska C, Barnett CR, Brand HN & Fawell JK 1987 A comparison of in vitro cytotoxicity assays and their application to water samples. Altern Lab Anim 15, 20–29.
Kawabata J, Mizuhatak , Sato E, Nishioka T, Aoyana Y & Kasai T 2003 6-Hydroxyflavonoids as alpha-glucosidase inhibitors from majoram Origanum majorana leaves. Biosci Biotechnol Biochem 67, 445–447.
Kurihara H, Fukami H, Kusumoto A, Toyoda Y, Shibata H, Matsui Y, Asami S & Tanaka T 2003 Hypoglycaemic action of Cyclocarya paliurus (Batal) Iljinskaja in normal and diabetic mice. Biosci Biotechnol Biochem 67, 877–880.
Laws A 2001 A new era in type 2 diabetes mellitus treatment?. Am J Med 111, 71–72.
Lilloja S, Mott DM, Spraul M, Ferraro R, Foley JE & Ravussin EInsulin resistance and insulin secretory dysfunction as precursor of non-insulin dependent diabetes mellitus. N Engl J Med 1993 329, 1988–1992.
McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YHA, O'Harte FPM, Yoon TW, Swanston-Flatt SK & Flatt PR 1996 Characterisation of a novel glucose responsive insulin secreting cell line, BRIN BD11, produced by electrofusion. Diabetes 45, 1132–1140.
MacLennan AH, Wilson DH & Taylor AW 1996 Prevalence and cost of alternative medicine in Australia. Lancet 347, 569–573.
Mandrup-Poulsen T 41998 Effect of a high monounsaturated fat diet rich in avocado in NIDDM patients. Diabetes Care 4, 311–315.
Miguel JC, Abdel-Wahab YHA, Mathias PC & Flatt PR 2003 Time-correlation between membrane depolarisation and intracellular calcium in insulin secreting BRIN-BD11 cells: studies using FLIPR. Cell Calcium 36, 43–50.
Oubre AY, Carlson TJ, King SR& Reavan GM 1997 From plant to patient: an ethnobotanical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia 40, 614–617.
Rhinehart BL, Robinson KM, Payne AJ, Wheatley MEFisher JL, Liu PS & Cheung W 1987 Castanospermine blocks the hyperglycaemic response to carbohydrates in vivo: a result of intestinal disaccharidase inhibition. Life Sci 41, 2325–2331.
Shinwari IM & Khan AM 2000 Folk use of medicinal herbs of Margalla Hills National Park, Islamabad. J Ethnopharmacol 69, 45–56.
Swanston-Flatt SK, Day C, Flatt PR & Bailey CJEvaluation of the antihyperglycaemic properties of traditional plant treatments for diabetes. In Frontiers in Diabetes Research: Lessons from Animal Diabetes, [E Shafrir]. London: Smith-Gordon and Company. 1991a Vol.3, pp.286–293.
Swanston-Flatt SK, Flatt PR, Day C & Bailey CJ 1991b Traditional dietary adjuncts for the treatment of diabetes mellitus. Proc Nutr Soc 50, 641–651.
UKPDS Perspectives in diabetes UKPDS Study 16 (1995) Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 44, 1249–1258.
Weragoda PB 1980 Some questions about the future of traditional medicine in developing countries. J Ethnopharmacol 2, 193–194.
Yoshikuni Y, 1998 Inhibition of intestinal a-glucosidase activity in postprandial hyperglycaemia by moraline and its n-alkyl derivatives. Agric Biol Chem 52, 121–128.